Results 41 to 50 of about 785,489 (353)

Amplification of cycline D1, c-myc and EGFR oncogenes in tumour samples of breast cancer patients [PDF]

Journal of Medical Biochemistry, 2013
Background: Breast cancer is the most common form of cancer in women. It arises from multiple genetic changes in oncogenes and tumor suppressor genes.
Tanić Nasta, Milinković Vedrana, Dramićanin Tatjana, Nedeljković Milica, Stanković Tijana, Milovanović Zorka, Šušnjar Snežana, Milošević Verica, Šosić-Jurjević Branka, Džodić Radan, Tanić Nikola   +10 more
doaj  

The efficacy and safety of first-line therapy for the epidermal growth factor receptor mutant non-small cell lung cancer in older versus younger patients: A pooled analysis of two randomized controlled trials

Cancer Research, Statistics, and Treatment, 2020
Background: There is a scarcity of data to guide the management of older patients with cancer. We therefore conducted this study to compare the outcomes and toxicities in older versus younger patients with an epidermal growth factor receptor (EGFR ...
Akhil Kapoor, Vanita Noronha, Vijay M Patil, Amit Joshi, Nandini Menon, Anuradha Chougule, Pratik Chandrani, Vaishakhi Trivedi, Vichitra Behel, Rajiv Kumar, Abhishek Mahajan, Amit Janu, Kumar Prabhash   +12 more
doaj   +1 more source

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer [PDF]

, 2016
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation.
Chater, E, De Bruin, E, Downward, J, Heynen, GJJE, Hu, Y, Li, H, Liu, Z, Pardo, OE, Roy, R, Seckl, MJS, Smit, EF, Stokes, W, Tang, H, Wang, Y   +13 more
core   +2 more sources

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

British Journal of Cancer, 2019
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung ...
A. Leonetti, Sugandhi Sharma, R. Minari, P. Perego, E. Giovannetti, M. Tiseo   +5 more
semanticscholar   +1 more source

Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)

International Journal of Oncology, 2021
Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), and substantially improves their
Jingyi He, Zhengrong Huang, Linzhi Han, Y. Gong, C. Xie   +4 more
semanticscholar   +1 more source

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp, Harreus, Ulrich, Reiter, Maximilian, Schwenk-Zieger, Sabina   +3 more
core   +1 more source

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Journal of experimental & clinical cancer research : CR, 2021
Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients.
Jing Zhou, Q. Ji, Qi Li
semanticscholar   +1 more source

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY

JTO Clinical and Research Reports
Introduction: The treatment landscape for people diagnosed with EGFR-mutated (EGFR-m) NSCLC has rapidly evolved, yet there remains limited self-reported information about the lived experience.
Jill Feldman, MA, Ivy Elkins, MBA, Zofia Piotrowska, MD, Bellinda L. King-Kallimanis, PhD, Tendai Chihuri, MD, Carly Johnson, BS, Alecia Clary, PhD, Teri Kennedy, MA, Upal Basu Roy, PhD, MPH   +8 more
doaj   +1 more source

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study

Patient Preference and Adherence, 2021
Holger Schirutschke, Peter Gross, Alexander Paliege, Christian Hugo University Hospital Carl Gustav Carus at the Technische, Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, GermanyCorrespondence: Holger ...
Schirutschke H, Gross P, Paliege A, Hugo C   +3 more
doaj  

Thyroid Function Disorders in Patients with Chronic Kidney Disease

Medical Journal of Babylon, 2022
Background: Various thyroid functional test abnormalities are commonly observed in chronic kidney disease (CKD) due to alterations in thyroid hormone synthesis, metabolism, and regulation.
Hussein Yousif Sinjari, Jassim Muhammed Ibrahim   +1 more
doaj   +1 more source